Sonic Incytes on its Series A raise of US$7.3 million to accelerate Velacur commercialization

Sonic Incytes Medical Corp., a health technology company focused on liver health, completed its US$7.3 million Series A with backing from Nimbus Synergies as the lead investor, and support from Nicola Wealth, Mint Venture Partners, Consortium Medteq, Wavemaker Three-Sixty Health, Gaingels and INP Capital, as well as notable angel investors.

Fasken advised Sonic Incytes with a team led by Roger A.C. Kuypers and Geoff Pedlow, and included Brandon Deans and Brock Euper (Corporate Finance).